HEIDELBERG PHARMA AG (HPHA.DE) Stock Price & Overview
FRA:HPHA • DE000A11QVV0
Current stock price
The current stock price of HPHA.DE is 3.02 EUR. Today HPHA.DE is up by 3.07%. In the past month the price increased by 3.07%. In the past year, price increased by 6.71%.
HPHA.DE Key Statistics
- Market Cap
- 141.276M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.56
- Dividend Yield
- N/A
HPHA.DE Stock Performance
HPHA.DE Stock Chart
HPHA.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to HPHA.DE. When comparing the yearly performance of all stocks, HPHA.DE is one of the better performing stocks in the market, outperforming 80.32% of all stocks.
HPHA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HPHA.DE. HPHA.DE may be in some trouble as it scores bad on both profitability and health.
HPHA.DE Earnings
HPHA.DE Forecast & Estimates
8 analysts have analysed HPHA.DE and the average price target is 5.61 EUR. This implies a price increase of 85.76% is expected in the next year compared to the current price of 3.02.
For the next year, analysts expect an EPS growth of -44.19% and a revenue growth -16.28% for HPHA.DE
HPHA.DE Groups
Sector & Classification
HPHA.DE Financial Highlights
Over the last trailing twelve months HPHA.DE reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS decreased by -35.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.43% | ||
| ROE | -248.59% | ||
| Debt/Equity | 3.47 |
HPHA.DE Ownership
HPHA.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.12 | 37.241B | ||
| 1AE | ARGENX SE | 25.1 | 37.241B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.407B | ||
| 2X1 | ABIVAX SA | N/A | 7.512B | ||
| ABVX | ABIVAX SA | N/A | 7.496B | ||
| GLPG | GALAPAGOS NV | N/A | 1.741B | ||
| GXE | GALAPAGOS NV | N/A | 1.74B | ||
| NANO | NANOBIOTIX | N/A | 1.309B | ||
| 6IV | INVENTIVA SA | N/A | 1.094B | ||
| IVA | INVENTIVA SA | N/A | 1.069B | ||
| PHIL | PHILOGEN SPA | 18.09 | 657.9M | ||
| GNFT | GENFIT | 815.2 | 425.025M | ||
| FYB | FORMYCON AG | N/A | 314.879M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About HPHA.DE
Company Profile
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 114 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
Company Info
IPO: 2006-11-13
HEIDELBERG PHARMA AG
Schriesheimer Strasse 101
Ladenburg BADEN-WUERTTEMBERG DE
Employees: 105
Phone: 49620310090
HEIDELBERG PHARMA AG / HPHA.DE FAQ
Can you describe the business of HEIDELBERG PHARMA AG?
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 114 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
What is the stock price of HEIDELBERG PHARMA AG today?
The current stock price of HPHA.DE is 3.02 EUR. The price increased by 3.07% in the last trading session.
Does HPHA stock pay dividends?
HPHA.DE does not pay a dividend.
How is the ChartMill rating for HEIDELBERG PHARMA AG?
HPHA.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists HPHA stock?
HPHA.DE stock is listed on the Frankfurt Stock Exchange exchange.
Is HEIDELBERG PHARMA AG (HPHA.DE) expected to grow?
The Revenue of HEIDELBERG PHARMA AG (HPHA.DE) is expected to decline by -16.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is HEIDELBERG PHARMA AG worth?
HEIDELBERG PHARMA AG (HPHA.DE) has a market capitalization of 141.28M EUR. This makes HPHA.DE a Micro Cap stock.